TWI561241B - Pharmaceutical composition for treating a metabolic syndrome - Google Patents

Pharmaceutical composition for treating a metabolic syndrome

Info

Publication number
TWI561241B
TWI561241B TW100101879A TW100101879A TWI561241B TW I561241 B TWI561241 B TW I561241B TW 100101879 A TW100101879 A TW 100101879A TW 100101879 A TW100101879 A TW 100101879A TW I561241 B TWI561241 B TW I561241B
Authority
TW
Taiwan
Prior art keywords
treating
pharmaceutical composition
metabolic syndrome
metabolic
syndrome
Prior art date
Application number
TW100101879A
Other languages
English (en)
Other versions
TW201141511A (en
Inventor
Mark Sommerfeld
Hans-Ludwig Schaefer
Oliver Boscheinen
Paul Habermann
Ercole Rao
Matthias Dreyer
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41718306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI561241(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TW201141511A publication Critical patent/TW201141511A/zh
Application granted granted Critical
Publication of TWI561241B publication Critical patent/TWI561241B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
TW100101879A 2010-01-21 2011-01-19 Pharmaceutical composition for treating a metabolic syndrome TWI561241B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10305070A EP2359843A1 (en) 2010-01-21 2010-01-21 Pharmaceutical composition for treating a metabolic syndrome

Publications (2)

Publication Number Publication Date
TW201141511A TW201141511A (en) 2011-12-01
TWI561241B true TWI561241B (en) 2016-12-11

Family

ID=41718306

Family Applications (2)

Application Number Title Priority Date Filing Date
TW105119851A TWI623320B (zh) 2010-01-21 2011-01-19 用於治療代謝症候群之醫藥組成物
TW100101879A TWI561241B (en) 2010-01-21 2011-01-19 Pharmaceutical composition for treating a metabolic syndrome

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW105119851A TWI623320B (zh) 2010-01-21 2011-01-19 用於治療代謝症候群之醫藥組成物

Country Status (33)

Country Link
US (4) US20130203651A1 (zh)
EP (7) EP2460527A1 (zh)
JP (3) JP5925130B2 (zh)
KR (2) KR20120123445A (zh)
CN (1) CN102753192B (zh)
AR (1) AR079939A1 (zh)
AU (2) AU2011208650B2 (zh)
BR (1) BR112012017949A2 (zh)
CA (1) CA2787131A1 (zh)
CL (1) CL2012002031A1 (zh)
CO (1) CO6592082A2 (zh)
CY (2) CY1116026T1 (zh)
DK (2) DK2525807T3 (zh)
ES (3) ES2529612T3 (zh)
HK (2) HK1173073A1 (zh)
HR (2) HRP20150029T1 (zh)
HU (1) HUE041442T2 (zh)
IL (2) IL220862A0 (zh)
LT (1) LT3216459T (zh)
MA (1) MA33931B1 (zh)
MX (2) MX336751B (zh)
NZ (1) NZ601306A (zh)
PL (2) PL2525807T3 (zh)
PT (2) PT3216459T (zh)
RS (1) RS53742B1 (zh)
RU (2) RU2593960C2 (zh)
SG (2) SG10201500465XA (zh)
SI (2) SI3216459T1 (zh)
TR (1) TR201820147T4 (zh)
TW (2) TWI623320B (zh)
UY (1) UY33194A (zh)
WO (1) WO2011089203A1 (zh)
ZA (1) ZA201204996B (zh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2349324T1 (en) 2008-10-17 2018-01-31 Sanofi-Aventis Deutschland Gmbh The combination of insulin and agonist GLP-1
AR078973A1 (es) 2009-11-13 2011-12-14 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
KR101836070B1 (ko) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
SI2611458T1 (sl) 2010-08-30 2017-01-31 Sanofi-Aventis Deutschland Gmbh Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
ES2748038T3 (es) 2011-07-01 2020-03-12 Ngm Biopharmaceuticals Inc Composiciones, usos y métodos para el tratamiento de trastornos y enfermedades metabólicos
EP2548570A1 (en) * 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
TWI559929B (en) * 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
BR112015004734A2 (pt) * 2012-09-07 2017-11-21 Sanofi Sa proteínas de fusão para tratar uma síndrome metabólica
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CA2927592C (en) 2013-10-28 2020-08-18 Ngm Biopharmaceuticals, Inc. Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
JP6837840B2 (ja) 2014-01-24 2021-03-10 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 結合タンパク質及びその使用方法
EP3104873B1 (en) * 2014-02-13 2019-09-04 Technische Universität München Fgf-8 for use in treating diseases or disorders of energy homeostasis
US10105442B2 (en) * 2014-05-07 2018-10-23 Novo Nordisk A/S Treatment of diabetes type 1 using GLP-1 and anti-IL-21
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN104383523A (zh) * 2014-10-22 2015-03-04 山西医科大学 Cjc-1131降糖药物在治疗阿尔茨海默病的用途
AU2015335844B2 (en) 2014-10-23 2020-09-03 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
HUE062573T2 (hu) 2014-12-12 2023-11-28 Sanofi Aventis Deutschland Glargin inzulin/lixiszenatid rögzített arányú készítmény
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EP3377090B1 (en) 2015-11-09 2021-04-07 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
BR112019012693A2 (pt) * 2016-12-22 2019-11-19 Sanofi Sa combinações de composto de fgf21/agonista do glp-1r com razão de atividade otimizada
JP2018110304A (ja) 2016-12-28 2018-07-12 パナソニックＩｐマネジメント株式会社 監視システム、監視方法、及びプログラム
US20220127322A1 (en) * 2017-03-14 2022-04-28 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
MX2020008096A (es) * 2018-01-31 2020-09-24 Sanofi Sa Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico.
US11679143B2 (en) 2018-02-08 2023-06-20 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
JP2021528422A (ja) * 2018-06-21 2021-10-21 サノフイＳａｎｏｆｉ 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ−１ｒアゴニストの組合せ
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
KR20210149366A (ko) * 2020-06-02 2021-12-09 주식회사 고바이오랩 Icam-2에 결합하는 물질을 유효성분으로 포함하는 대사질환 예방 또는 치료용 약학 조성물
US20220010021A1 (en) 2020-07-02 2022-01-13 Sanofi FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides
CN114712488B (zh) * 2021-01-04 2023-12-26 华领医药技术（上海）有限公司 Dorzagliatin和胰高血糖素样肽-1类似物的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255045A1 (en) * 2007-03-30 2008-10-16 Ambrx, Inc. Modified FGF-21 Polypeptides and Their Uses
WO2009020802A2 (en) * 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
AU612141B2 (en) 1987-02-25 1991-07-04 Novo Nordisk A/S Novel insulin derivatives
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
WO1995007931A1 (en) 1993-09-17 1995-03-23 Novo Nordisk A/S Acylated insulin
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP2002112772A (ja) * 2000-07-10 2002-04-16 Takeda Chem Ind Ltd 新規ポリペプチドおよびそのｄｎａ
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
CA2497794A1 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
BRPI0411112A (pt) 2003-06-12 2006-07-18 Lilly Co Eli proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga
AU2004303783A1 (en) 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1727559A1 (en) 2004-01-26 2006-12-06 Eli Lilly And Company Use of fgf-21 and a thiazolidinedione for treating type 2 diabetes
JP2007531715A (ja) 2004-03-17 2007-11-08 イーライ リリー アンド カンパニー グリコール結合ｆｇｆ−２１化合物
JP2008506635A (ja) 2004-05-13 2008-03-06 イーライ リリー アンド カンパニー Ｆｇｆ−２１融合タンパク質
EP1789443A1 (en) 2004-09-02 2007-05-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
BRPI0514790A (pt) 2004-09-02 2008-06-24 Lilly Co Eli muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
EP1831371A2 (en) 2004-12-14 2007-09-12 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP2068910A2 (en) * 2006-08-04 2009-06-17 Amylin Pharmaceuticals, Inc. Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition
UY30820A1 (es) * 2006-12-21 2008-07-03 Centocor Inc Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
US20100286067A1 (en) 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
WO2010006214A1 (en) * 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
AU2010246038A1 (en) * 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
CN102802657A (zh) * 2009-06-11 2012-11-28 诺沃-诺迪斯克有限公司 用于治疗2型糖尿病的glp-1和fgf21组合
EP2548570A1 (en) * 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255045A1 (en) * 2007-03-30 2008-10-16 Ambrx, Inc. Modified FGF-21 Polypeptides and Their Uses
WO2009020802A2 (en) * 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity

Also Published As

Publication number Publication date
RU2016124562A3 (zh) 2019-09-20
CY1121423T1 (el) 2020-05-29
CO6592082A2 (es) 2013-01-02
EP3607964A1 (en) 2020-02-12
NZ601306A (en) 2013-11-29
AU2016244202B2 (en) 2018-03-01
ES2930750T3 (es) 2022-12-21
EP3357503B1 (en) 2019-10-30
RU2732703C2 (ru) 2020-09-21
IL267980A (en) 2019-08-29
EP2525807B1 (en) 2014-11-12
KR20120123445A (ko) 2012-11-08
MX336751B (es) 2016-01-29
SG10201500465XA (en) 2015-03-30
PL3216459T3 (pl) 2019-04-30
DK3216459T3 (en) 2019-01-21
PT3216459T (pt) 2019-01-11
RU2016124562A (ru) 2018-11-30
HRP20150029T1 (en) 2015-03-27
TW201703792A (zh) 2017-02-01
US20180236033A1 (en) 2018-08-23
EP2359843A1 (en) 2011-08-24
UY33194A (es) 2011-08-31
CA2787131A1 (en) 2011-07-28
ZA201204996B (en) 2013-02-27
DK2525807T3 (en) 2015-02-09
EP3357503A1 (en) 2018-08-08
US20130203651A1 (en) 2013-08-08
CL2012002031A1 (es) 2012-12-14
CN102753192A (zh) 2012-10-24
JP5925130B2 (ja) 2016-05-25
IL267980B (en) 2020-03-31
ES2529612T3 (es) 2015-02-23
AU2016244202A1 (en) 2016-11-03
LT3216459T (lt) 2019-01-10
EP2460527A1 (en) 2012-06-06
EP2754449A1 (en) 2014-07-16
KR20180049194A (ko) 2018-05-10
TW201141511A (en) 2011-12-01
EP2525807A1 (en) 2012-11-28
ES2703581T3 (es) 2019-03-11
RU2012135686A (ru) 2014-02-27
RU2593960C2 (ru) 2016-08-10
US20160279199A1 (en) 2016-09-29
EP3607964B1 (en) 2022-08-31
JP2018095659A (ja) 2018-06-21
TR201820147T4 (tr) 2019-01-21
WO2011089203A1 (en) 2011-07-28
AR079939A1 (es) 2012-02-29
JP2013518035A (ja) 2013-05-20
CN102753192B (zh) 2015-09-23
PL2525807T3 (pl) 2015-04-30
BR112012017949A2 (pt) 2017-06-27
HRP20182158T1 (hr) 2019-02-22
PT2525807E (pt) 2015-02-04
JP2016128483A (ja) 2016-07-14
MA33931B1 (fr) 2013-01-02
AU2011208650A1 (en) 2012-08-09
RS53742B1 (en) 2015-06-30
SI3216459T1 (sl) 2019-02-28
JP6521880B2 (ja) 2019-05-29
US20150231210A1 (en) 2015-08-20
CY1116026T1 (el) 2017-01-25
SI2525807T1 (sl) 2015-02-27
HK1173073A1 (zh) 2013-05-10
SG182652A1 (en) 2012-08-30
MX2012008092A (es) 2012-07-30
HK1259492A1 (zh) 2019-11-29
EP3216459B1 (en) 2018-09-26
TWI623320B (zh) 2018-05-11
IL220862A0 (en) 2012-09-24
AU2011208650B2 (en) 2016-07-14
HUE041442T2 (hu) 2019-05-28
EP3216459A1 (en) 2017-09-13
MX361922B (es) 2018-12-19

Similar Documents

Publication Publication Date Title
IL267980B (en) A pharmaceutical preparation for the treatment of metabolic syndrome
HK1246170A1 (zh) 藥物組合物
AP3864A (en) Pharmaceutical composition
LT2619182T (lt) Farmacinė kompozicija
IL225457A0 (en) Pharmaceutical composition
GB201118232D0 (en) Pharmaceutical composition
ZA201304633B (en) A pharmaceutical composition
GB201010453D0 (en) Pharmaceutical composition
HK1189158A1 (zh) 藥用組合物
EP2774917A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
ZA201302012B (en) Low dose pharmaceutical composition
EP2727593A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING NICORANDIL
EP2711010A4 (en) PHARMACEUTICAL COMPOSITION
HUP1100444A2 (en) Pharmaceutical composition
GB201001911D0 (en) Pharmaceutical composition
ZA201201003B (en) A pharmaceutical composition
HUP1100445A2 (en) Pharmaceutical composition
GB201019775D0 (en) Pharmaceutical composition